Corbenic Partners’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Corbenic Partners’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$0	Hold	804	–	–	﹤0.01%	273
2017 Q3	$0	Hold	804	–	–	﹤0.01%	280
2017 Q2	$0	Hold	804	–	–	﹤0.01%	216
2017 Q1	$0	Hold	804	–	–	﹤0.01%	233
2016 Q4	$0	Hold	804	–	–	﹤0.01%	231
2016 Q3	$0	Hold	804	–	–	﹤0.01%	242
2016 Q2	$0	Hold	804	–	–	﹤0.01%	207
2016 Q1	$0	Hold	804	–	–	﹤0.01%	212
2015 Q4	$0	Buy	+804	New	+$114	﹤0.01%	222
2015 Q2	–	Sell	-804	Closed	-$1K	–	169
2015 Q1	$1K	Buy	+804	New	+$562	﹤0.01%	159

Other funds holding GCVRZ

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

MCM

Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

BCM

Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

NGA

New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Corbenic Partners's GCVRZ Position: Q4 2017 in Review

Corbenic Partners held its Sanofi Contingent Value Rights (GCVRZ) position steady in Q4 2017 at 804 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #273.

Corbenic Partners first reported a position in GCVRZ in Q1 2015 and has held it in 10 quarters since. The position peaked at $1K in Q1 2015. 105 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2017.

Corbenic Partners held 804 shares of Sanofi Contingent Value Rights worth $0 as of Q4 2017.
Corbenic Partners left its Sanofi Contingent Value Rights share count unchanged in Q4 2017.
Sanofi Contingent Value Rights made up ﹤0.01% of Corbenic Partners's portfolio in Q4 2017, its #273 holding.
Corbenic Partners first reported a position in Sanofi Contingent Value Rights in Q1 2015 and has held it in 10 quarters since.
Corbenic Partners's Sanofi Contingent Value Rights position peaked at $1K in Q1 2015.
105 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2017.

Based on Corbenic Partners's 13F filing for Q4 2017, filed 25 Jan 2018.